Pacific Biosciences of California, Inc.· PACB

🇺🇸 US · MicroBroad USNASDAQ

Healthcare Medical - Devices Website

Price: $1.38
Day: +2.99%
Mkt Cap: $428.63M
52W Range: $1.07 – $2.73
Volume: 6.23M
Beta: 2.31

5D Framework

Company Overview

Snapshot of fundamentals, performance, and 5D scores.

5D scores: Quality 1.3, Peers 2.4, Valuation 5.0, Analysts 2.8, Holdings 3.3 (out of 5)
Market: $1.38 a share, market cap $428.63M, +12.2% over 12 months
Company: Healthcare · Medical - Devices, 485 employees, NASDAQ

Blog

Company Profile

Business fundamentals and company information

Business Description

Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.

Key Details

CEO

Mark Van Oene

Employees

485

Headquarters

Menlo Park, CA, US

IPO Date

Oct 2010

Exchange

NASDAQ Global Select

Phone

650 521 8000

Healthcare · Medical - Devices

SEC filings

10-KFeb 25, 2026 10-QAug 6, 2026 8-KAug 5, 2026

Price Performance

Recent price action and historical returns

Price Performance

$1.38

Historical Returns

Price performance over time

1 Day

+2.99%

5 Day

+8.66%

1 Month

+21.05%

3 Months

-1.43%

6 Months

-1.43%

YTD

-26.20%

1 Year

+12.20%

3 Years

-85.74%

5 Years

-95.31%

10 Years

-85.15%

Revenue Analysis

How the business makes money, by product and geography

2025 revenue · 4 products

Revenue to Profit Flow · 2025

How revenue flows through the P&L: Products → Total Revenue → COGS → Gross Profit → operating costs (R&D, SG&A). Operating costs ran past gross profit this year, so the shortfall enters as its own band and the rest of the P&L is listed under the chart.

Learn how to read flow diagrams

Below the line. Nothing flows through an operating loss, so these are shown as figures rather than as flows.

Operating Loss-$557.56M
Other income$18.46M
Interest-$6.95M
Tax-$318.00K
Net Loss-$546.38M

5D Framework

Five lenses on the stock. Click any card to dive deeper.

Quality

Business fundamentals

1.3/5

Poor

View Details

Peers

Competitive position

2.4/5

Weak

View Details

Valuation

Model-based valuation (vs. price)

5.0/5

Well below estimate

View Details

Analysts

Wall Street sentiment

2.8/5

Neutral

View Details

Holdings

Smart money flows

3.3/5

Neutral

View Details

How to read these dimensions

The five dimensions are independent lenses on a company, not a single combined score. Read them together rather than in isolation: where one dimension scores differently from the others is often the most useful place to focus your own research. Each score is built from rules and weights you can adjust, so treat them as a transparent starting point for your analysis, not a recommendation to buy or sell.